City Therapeutics

Drug Discovery · Cambridge, MA · Founded 2024 · Privately Held (backing)

Operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases. City Therapeutics is based in Cambridge, MA and was founded in 2024. It is valued at about $285 million as of Oct 2026, set by institutional fund marks. It has raised $140 million across 1 recorded round; the latest was a $135 million Series A in Oct 2024.

PMV mark · valuation
$285.5M
Oct 2026
Priced at
its Series A
Oct 2024
Total raised
$139.5M
Last round
Early Stage VC (Series A)
Oct 2024
How much has City Therapeutics raised?
$139.5Macross 1 recorded rounds · Oct 2024 – Oct 2024

Most recently, City Therapeutics raised $135.0M in its Early Stage VC (Series A) (Oct 2024).

Free account
More of City Therapeutics with a free account
  • ·Watch City Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

City Therapeutics round by round

1 rounds
Oct 2024Early Stage VC (Series A)$135.0M▮
+ 1 more investors · free account

How much has City Therapeutics raised?

City Therapeutics has raised $140 million across 1 recorded round since 2024. The largest was a $135 million Series A in Oct 2024.

City Therapeutics investors

8 investors are on record for City Therapeutics, including Fidelity Management & Research Company, ARCH Venture Partners, The Invus Group and Rock Springs Capital. The Series A in Oct 2024 drew 7 investors.

For fundraisers
Raising for a company like City Therapeutics?

8 investors have backed City Therapeutics — start your target list with the firms already writing checks in drug discovery.

See all 8 investors →

Frequently asked about City Therapeutics

How much has City Therapeutics raised?
City Therapeutics has raised $139.5M in total across 1 recorded funding rounds.
When was City Therapeutics's last funding round?
City Therapeutics's most recent recorded round was Early Stage VC (Series A) in Oct 2024, raising $135.0M.